Japan Phase III Start Cements Roxadustat’s Lead
Executive Summary
Astellas/FibroGen's oral candidate for anemia in chronic kidney disease has moved into Phase III in Japan on the basis of promising Phase II results, cementing the global development lead for the first-in-class product and taking it closer to a potentially big market.
You may also be interested in...
Bayer Wary Of Future Competition In Renal Anemia Market
The race to market for HIF-PH inhibitors to treat anemia associated with chronic kidney disease is highly competitive and will be complicated by the expected launch of biosimilar erythropoiesis-stimulating agents.
Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Need a specific report? 1000+ reports available
Buy Reports